Additional Technology Sample Clauses
Additional Technology. It is anticipated that Licensor may from time to time develop additional technology. In the event Licensor desires to market, distribute, or otherwise exploit any additional technology relating to the manufacture of a wheel-tire assembly that is not included within the above defined Technology (the "Additional Technology") in the World-wide Territory of Licensee, Licensor shall provide Licensee with a written notice (the "Initial Notice") setting forth full details concerning the Additional Technology, and Licensee shall have the exclusive right and option to have the Additional Technology made subject to this Agreement at any time during a period of 90 days following the date such Initial Notice is given. Licensee can exercise such option by delivery of a notice of its intent to do so within the option period. If Licensee does not exercise its option within the prescribed period, Licensor shall be entitled to enter into any agreement respecting the Additional Technology within the World-wide Territory of Licensee with any other entity. If Licensee is granted rights to Additional Technology, such rights shall be subject to all the terms and provisions of this Agreement and the Additional Technology shall be treated as Technology under this Agreement.
Additional Technology. During the Research Term, if either party believes that technology related to the subject matter of the Research that is Controlled by such party or a Third Party ("Additional Technology") would be valuable or necessary to the Research in the Field hereunder, such party shall present such technology, along with a written report with respect thereto, to the Research Management Committee. The Research Management Committee shall then determine whether licenses to, and/or acquisitions of, such Additional Technology shall be made, the party that shall approach and negotiate with any Third Parties and the terms of any agreements with any Third Parties, including, without limitation, payments for sponsored research. No such Third Party license and/or acquisition shall be effective with respect to the other party unless and until such other party has specifically agreed in writing to abide by the applicable terms and conditions of any such license and/or acquisition (other than payment terms, which are provided for in Sections 6.2 and 7.2 below). It is understood and agreed that with respect to all Additional Technology, Corixa's rights shall be limited to the Corixa Exclusive Field and GenQuest's rights shall be limited to the GenQuest Exclusive Field. Notwithstanding the foregoing, this Section 4.5 shall not be deemed to preclude either party from acquiring Additional Technology.
Additional Technology. During the Development Program Term, if SB or Aphton believe that technology related to the subject matter of the Development Program that is controlled by a Third Person, which may include new lmmunogens, adjuvants and/or Blocking Patents ("Additional Technology") would be valuable or necessary to the Development Program in the Field hereunder Aphton or SB as appropriate shall present such Additional Technology to the Steering Committee along with a written report. The Steering Committee shall then determine, except for Blocking Patents which shall be at SB's sole discretion subject to other provisions contained herein, whether licenses to, and/or acquisitions of, such Additional ------------------------ * The redacted portions of this document have been omitted pursuant to a request for confidential treatment and such redacted portions have been filed separately with the Securities and Exchange Commission. Technology should be made, and SB shall approach and negotiate the terms of any agreement(s) with any Third Person including, without limitation payments for sponsored research. No such Third Person license and/or acquisition shall be effective with respect to SB unless and until SB has specifically agreed in writing to abide by the applicable terms and conditions of any such license and/or acquisition.
Additional Technology. 14 4.6 Internal Corixa Gene Discovery Research ..........................14 4.7 Limitations ......................................................14 ARTICLE 5
Additional Technology. Any Invention that is [CONFIDENTIAL TREATMENT REQUESTED]/*/ at any time on or before [CONFIDENTIAL TREATMENT REQUESTED]/*/, shall automatically be included within the definition of “Technology” for purposes of this Agreement (and any patents or patent applications relating to such Inventions shall automatically be added to Schedule 1). EXACT shall promptly notify LABCORP in writing of all such Inventions. In addition, EXACT shall provide notice to LABCORP of any Invention that is [CONFIDENTIAL TREATMENT REQUESTED]/*/ at any time after [CONFIDENTIAL TREATMENT REQUESTED]/*/ during the Term of this Agreement but prior to [CONFIDENTIAL TREATMENT REQUESTED]/*/ (an “Applicable EXACT Invention”). Upon delivery of such notice and for a period of [CONFIDENTIAL TREATMENT REQUESTED]/*/ days thereafter, EXACT agrees to [CONFIDENTIAL TREATMENT REQUESTED]/*/. Notwithstanding the foregoing, EXACT reserves the right to [CONFIDENTIAL TREATMENT REQUESTED]/*/, in its sole discretion. However, in the event that[CONFIDENTIAL TREATMENT REQUESTED]/*/, and EXACT [CONFIDENTIAL TREATMENT REQUESTED]/*/, then in each such case EXACT shall [CONFIDENTIAL TREATMENT REQUESTED]/*/.
Additional Technology. (a) If at any time during the Term, QLT and/or Xenova reasonably determine that any technology controlled by a Third Party ("ADDITIONAL TECHNOLOGY") may be necessary or useful for the development or commercialization of the Drug and/or the Product in the Field in any country of the world, QLT or Xenova, as appropriate, shall present such Additional Technology, along with a written report with respect thereto, to the Development Committee (or in the event that the Development Committee has been dissolved, to the other party), which shall then consider the acquisition or licensing of the Additional Technology, but the Development Committee shall have no power to require either party to enter into any agreement, or have any financial or other commitments, with respect to any Additional Technology.
(b) In the case of Additional Technology that may be necessary or useful in the Field, the Development Committee (or in the event that the Development Committee has been dissolved, the parties) shall then determine, whether licenses to, and/or acquisitions of, such Additional Technology are desirable, and what recommendations to make to the parties as to which party shall approach and negotiate with the Third Party.
(c) In negotiating any agreements for the licensing or acquisition of Additional Technology under this Section 8.3, the party conducting such negotiations shall, on an ongoing basis throughout such negotiations, consult with the other party to ensure that the scope of the Intellectual Property rights licensed or otherwise acquired are adequate for the uses contemplated by the other party for the Additional Technology. The parties intend that each party shall be licensed in respect of its territory directly by the licensing party.
(d) The costs of licensing or otherwise acquiring any Additional Technology under this Section 8.3 shall be borne, on a territory-by-territory and field-by-field basis, by the party that has rights in that territory and field in respect of Drug and/or Product.
(e) In the absence of agreement to proceed with the licensing or acquisition of any Additional Technology hereunder, nothing in this Section 8.3 shall be deemed to preclude either party from licensing and/or acquiring such Additional Technology for its own benefit.
Additional Technology. All Additional Trademark Product Technology offered by Licensor, pursuant to SECTION 3.0 of this Agreement, and accepted by Licensee to manufacture, distribute, market, and sell under or in association with the Trademark pursuant to the terms and conditions of this Agreement shall be identified and listed on EXHIBIT B upon acceptance of the Additional Trademark Product Technology by Licensee. All Additional Non-Trademark Product Technology offered by Licensor, pursuant to SECTION 3.0 of this Agreement, and accepted by Licensee to manufacture, distribute, market and sell products made from the Additional Non-Trademark Product Technology pursuant to the terms and conditions of this Agreement shall be identified and listed on EXHIBIT C upon acceptance by Lessee. All Additional Technology that becomes a part of the terms and conditions of this Agreement is limited to the technology identified and listed on EXHIBIT B and EXHIBIT C.
Additional Technology. Startek agrees that it has the necessary technology and staffing capabilities to meet the requirements herein as of the Effective Date of this SOW. Requests for additional hardware and software shall be subject to the Change Management section of the MSA.
Additional Technology. During the Term, in the event AOL elects to license additional Viewpoint technology including, but not limited to, any additional Viewpoint technology relating to the use of Viewpoint Content on any platform (such as AOL TV) not otherwise made available by Viewpoint on a commercial basis (collectively, the “Additional Technology”), the Parties shall mutually agree on the terms and conditions pursuant to which Viewpoint shall provide such Additional Technology to AOL; provided, however, that in the event that any fees are due for such Additional Technology, then any such fees associated with such Additional Technology shall be no less favorable than the fees paid by any other Viewpoint customer with respect to technology having a license scope and usage similar to the Additional Technology. If the Additional Technology results in a modification or enhancement to the Media Player Software, the Media Player Software License granted to AOL in Section 2.1(c) shall include the Media Player as so modified or enhanced. Notwithstanding anything to the contrary set forth in this Agreement, if, during the Term, AOL engages Viewpoint to develop and provide to AOL technology which represents an extension of the Media Player Software for use on a PC platform, including but not limited to such extensions comprised of Components to the Media Player Software created solely for the benefit of AOL and not intended for general distribution, license rights thereto shall be deemed to covered by payments made under this Agreement.
Additional Technology. In addition to the foregoing, and subject to --------------------- the terms and conditions of this Agreement, InterTrust shall make available to NatWest: (i) Update Releases [*] (beyond the Support Fee set forth in Section 5.1((c)) hereof) for a period of [*] years following the Effective Date; and (ii) New Releases (1) [*] (beyond the Support Fee) for a period of [*] years after the Effective Date and, (2) for the subsequent [*] years [*]. Notwithstanding the foregoing, NatWest shall be entitled to obtain in accordance with the provisions of this Section 2.1((b)): (A) [*] (beyond the Support Fee and/or such fees as set forth in Sections 5.1((a))((iv)) and 5.1((a))((v)) InterTrust's Commerce 2.0 software release and, whether in the form of one or more New Releases and/or Update Releases, software that provides those functions specified in Section I.B. of Exhibit A hereto (the "Requested Functionality"), ----------------------- as available from InterTrust at any time during the term of this Agreement; and (B) such portions of New Releases and/or Update Releases, as applicable, made available by InterTrust after the end of the [*] year following the Effective Date, if any, that are strictly necessary for NatWest Products and associated services to remain in Compliance with then existing InterTrust Specifications and/or subsequent New Specification pursuant to Section 4.1((b)) hereof, provided that such New Release and/or Update Release portions shall be -------- made available to NatWest [*]. Further notwithstanding the foregoing, the revenue sharing royalties set forth in Section 5.1((b)) shall be payable to InterTrust as set forth therein. Any Update Releases and/or New Releases that NatWest is entitled to receive pursuant to this Section 2.1((b)) shall be supplied to NatWest at reasonably the same time (but in no event later than five (5) business days after) when such software is first made available to any Core Partner and before such product is made generally available publicly, except that the foregoing shall not restrict InterTrust from providing Update Releases and/or New Releases to customers and/or making such Update Releases generally available publicly where such Update Releases and/or New Releases provide, in material part, updated software responsive to security, interoperability and/or integrity concerns. The Parties acknowledge and agree that nothing in this Section 2.1 shall be construed to require InterTrust to make any InterTrust techno...